Introduction:
Leading Indian pharmaceutical manufacturer has secured a ₹1,760 crore agreement with a global pharma giant to produce oral liquid formulations for the European market. The collaboration marks a significant milestone in expanding India’s presence in regulated markets.
Also Read: Stocks to Consider for This New Year 2025
Share price movement of Akums Drugs:
On December 24, 2024, Akums Drugs and Pharmaceuticals Ltd opened at ₹604.80, up 1.16% from its previous close of ₹597.95. The stock reached a high of ₹625.55 and a low of ₹576.65. By 2:23 PM, it traded at ₹593.00, with a market cap of ₹9,333.46 crore.
Akums Drugs Secures ₹1,760 Crore CDMO Deal:
Akums Drugs and Pharmaceuticals Ltd. has signed a ₹1,760 crore long-term agreement with a leading global pharma company to manufacture and supply oral liquid formulations in Europe. Commercial production is set to commence in 2027 and continue till 2032.
The project includes an upfront payment of ₹880 crore for product development and site approvals, with regulatory approvals anticipated by 2026. Akums will utilize its European-certified facilities, adding another dosage form to its extensive portfolio for the regulated markets.
Managing Directors Sanjeev Jain and Sandeep Jain highlighted this partnership as a major achievement, enhancing Akums’ global presence while enabling multinational firms to optimize manufacturing costs and ensure a robust supply chain through India’s world-class facilities.
Recent news on Akums Drugs:
As of November 26, 2024, Akums Drugs and Pharmaceuticals announced that its subsidiary, Maxcure Nutravedics, has partnered with Jagdale Industries to market ready-to-drink nutritional beverages, tapping into the growing electrolyte RTD market in India.
Stock performance of Akums Drugs for Period of 1 week and 1 month:
Akums Drugs and Pharmaceuticals Ltd delivered a 3.27% return over the past week, showcasing short-term growth. However, its one-month performance saw a decline of 6.59%, reflecting recent market fluctuations affecting its stock value.
Also Read: Stocks To Consider For Christmas
Shareholding pattern of Akums Drugs:
| Sep 2024 | Aug 2024 | |
| Promoter | 75.30% | 75.30% |
| FII | 7.30% | 5.30% |
| DII | 7.50% | 7.60% |
| Public | 7.10% | 9.10% |
| Others | 2.70% | 2.80% |
About Akums Drugs:
Akums Drugs and Pharmaceuticals Ltd (NSE: AKUMS) is a leading CDMO specializing in pharmaceutical formulations, APIs, R&D, and regulatory services. Accredited globally, it serves diverse therapeutic areas, including anti-infective, respiratory, and diabetes.
Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time The securities quoted are exemplary and are not recommendatory.
